We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Gen2 Isthmus-Dependent Atrial Flutter Ablation Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00606463
Recruitment Status : Completed
First Posted : February 4, 2008
Last Update Posted : April 25, 2017
Sponsor:
Information provided by (Responsible Party):
St. Jude Medical

Brief Summary:
Irrigated catheter for ablation of isthmus-dependent atrial flutter

Condition or disease Intervention/treatment
Atrial Flutter Device: Cardiac Ablation (Gen2 Cardiac Ablation System)

Detailed Description:
This study intends to use an investigational irrigated catheter for ablation of isthmus-dependent atrial flutter

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Gen2 Cardiac Ablation System Isthmus-Dependent Atrial Flutter Study
Study Start Date : February 2008
Primary Completion Date : August 2008
Study Completion Date : January 2009

Arm Intervention/treatment
Experimental: (Gen2 Cardiac Ablation System)
Ablation of isthmus-dependent atrial flutter
Device: Cardiac Ablation (Gen2 Cardiac Ablation System)
Ablation of isthmus-dependent atrial flutter



Primary Outcome Measures :
  1. Incidence of intraprocedural, serious cardiac adverse event [ Time Frame: 7 days post-procedure ]
    Defined as the Incidence of intraprocedural, serious cardiac adverse event


Other Outcome Measures:
  1. Bi-direction block and non-inducibility of atrial flutter [ Time Frame: Procedural ]
    Acute Procedure success defined as bi-directional block and non-inducibility of atrial flutter



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Scheduled for ablation of isthmus-dependent atrial flutter

Exclusion Criteria:

  • Prior ablation of isthmus-dependent atrial flutter
  • Atypical or scar flutter
  • Significant heart disease
  • Intracardiac thrombus
  • Prior cardiac surgery (within 1 month)
  • Contraindication to heparin

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00606463


Locations
United States, Alabama
University of Alabama Birmingham
Birmingham, Alabama, United States
United States, New Jersey
St. Barnabus Medical Center
West Orange, New Jersey, United States
United States, Pennsylvania
Doylestown Hospital
Doylestown, Pennsylvania, United States
Sponsors and Collaborators
St. Jude Medical
Investigators
Principal Investigator: Vance Plumb, MD University of Alabama at Birmingham

Responsible Party: St. Jude Medical
ClinicalTrials.gov Identifier: NCT00606463     History of Changes
Other Study ID Numbers: 0611.1
First Posted: February 4, 2008    Key Record Dates
Last Update Posted: April 25, 2017
Last Verified: April 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Pediatric Postmarket Surveillance of a Device Product: No

Additional relevant MeSH terms:
Atrial Flutter
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes